How Has the Autologous Stem Cell And Non-Stem Cell Based Therapies Market Evolved Historically and What is its Current Size?
The autologous stem cell and non-stem cell based therapies market has seen considerable growth due to a variety of factors.
• The autologous stem cell and non-stem cell based therapies market has seen rapid growth in recent years. It is projected to rise from $9.96 billion in 2024 to $11.59 billion in 2025, at a compound annual growth rate (CAGR) of 16.5%.
This growth is driven by the rising prevalence of cancer and diabetes, the growing elderly population, increased healthcare awareness, rising research and development, more clinical trials, and more regulatory approvals.
What is the Forecasted Market Size and CAGR for the Autologous Stem Cell And Non-Stem Cell Based Therapies Market?
The autologous stem cell and non-stem cell based therapies market is expected to maintain its strong growth trajectory in upcoming years.
• The autologous stem cell and non-stem cell based therapies market is expected to experience rapid growth, reaching $21.07 billion by 2029, with a CAGR of 16.1%.
This growth is driven by the rising prevalence of targeted diseases, an aging population, neurodegenerative diseases, cancer cases, demand for skin transplantation, and advancements in regenerative medicine. Trends include AI integration, off-the-shelf allogeneic stem cell products, expanded reimbursement policies, and gene editing technology adoption.
What Key Factors and Trends Are Driving The Growth Autologous Stem Cell And Non-Stem Cell Based Therapies Market?
The rising demand for personalized therapies is expected to drive growth in the autologous stem cell and non-stem cell-based therapies market. Personalized therapies are becoming more popular due to advances in genetics and technology that allow for treatments tailored to individuals’ genetic profiles and preferences. The Personalized Medicine Coalition reported that 12 new personalized medicines were approved in 2022, representing 34% of all new therapies, signaling a significant increase. Therefore, the demand for personalized therapies is boosting the autologous stem cell and non-stem cell-based therapies market.
What Are The Market Segments In The Autologous Stem Cell And Non-Stem Cell Based Therapies Market?
The autologous stem cell and non-stem cell based therapies market covered in this report is segmented –
1) By Type: Autologous Stem Cells, Autologous Non-Stem Cells, Other Types
2) By Application: Cancer, Neurodegenerative Disorders, Cardiovascular Disease, Orthopedic Diseases, Other Applications
3) By End-User: Hospitals, Ambulatory Surgical Centers, Research Facilities, Other End Users
Subsegments:
1) By Autologous Stem Cells: Hematopoietic Stem Cells, Mesenchymal Stem Cells, Neural Stem Cells, Endothelial Stem Cells
2) By Autologous Non-Stem Cells: Platelet-Rich Plasma (Prp), Adipose-Derived Cells, Peripheral Blood Cells
3) By Other Types: Exosome-Based Therapies, Tissue-Engineered Constructs
Pre-Book The Autologous Stem Cell And Non-Stem Cell Based Therapies Global Market Report 2025 Report For Swift Delivery And Comprehensive Insights:
What New Trends Are Influencing The Autologous Stem Cell And Non-Stem Cell Based Therapies Market?
Companies in the autologous stem cell and non-stem cell-based therapies market are advancing tumor-derived autologous T cell immunotherapy to enhance personalized cancer treatments. This therapy involves extracting T cells from a patient's tumor, expanding and activating them in the lab, and reinfusing them to boost the immune system's ability to target cancer cells. For example, in February 2024, Iovance Biotherapeutics, a US-based biotech company, received FDA approval for Amtagvi (lifileucel), the first cellular therapy for treating melanoma in adults. Lifileucel uses tumor-infiltrating lymphocytes (TILs) to help the immune system recognize and attack cancer cells more effectively.
Who Are the Key Players In The Autologous Stem Cell And Non-Stem Cell Based Therapies Market?
Major companies operating in the autologous stem cell and non-stem cell based therapies market are:
• Bayer AG
• Novartis AG
• Takeda Pharmaceutical Company Limited
• Gilead Sciences Inc.
• Merck & Co. Inc.
• Stemcell Technologies Inc.
• Dendreon Corporation
• Vericel Corporation
• Sangamo Therapeutics Inc.
• NEOSTEM
• Orgenesis Inc.
• Adaptimmune Therapeutics
• Stempeutics Research Pvt Ltd.
• MEDIPOST
• Castle Creek Biosciences Inc.
• BrainStorm Cell Limited
• Athersys Inc.
• Cytori Therapeutics Inc.
• Opexa Therapeutics
• Gamida Cell
• Regen BioPharma Inc.
• RepliCel Life Sciences
• InGeneron Inc.
• BioCardia Inc.
• ReNeuron Group
What Are The Regional Insights Into The Autologous Stem Cell And Non-Stem Cell Based Therapies Market?
North America was the largest region in the autologous stem cell and non-stem cell based therapies market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the autologous stem cell and non-stem cell based therapies market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
